Last reviewed · How we verify
SULTAMICILLIN — Competitive Intelligence Brief
discontinued
sultamicillin
Infectious Disease
Small molecule
Live · refreshed every 30 min
Target snapshot
SULTAMICILLIN (SULTAMICILLIN). Sultamicillin works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| SULTAMICILLIN TARGET | SULTAMICILLIN | discontinued | sultamicillin |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (sultamicillin class)
- · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- SULTAMICILLIN CI watch — RSS
- SULTAMICILLIN CI watch — Atom
- SULTAMICILLIN CI watch — JSON
- SULTAMICILLIN alone — RSS
- Whole sultamicillin class — RSS
Cite this brief
Drug Landscape (2026). SULTAMICILLIN — Competitive Intelligence Brief. https://druglandscape.com/ci/sultamicillin. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab